Wapnick Pamela 4

What Happened Pamela Wapnick, Chief Financial Officer of Metagenomi Therapeutics, Inc. (MGX), received equity awards reported on a Form 4 covering transactions dated April 1, 2026. The filing shows a grant of 24,000 restricted stock units (RSUs) and a separate derivative award covering 144,000 shares (an option-style award), both reported at $0.00 per share. These are compensation awards rather than open-market purchases or sales.

Key Details

• Transaction date: April 1, 2026; Form 4 filed April 3, 2026 (timely filing).
• Awards: 24,000 RSUs (reported as A) and 144,000-share derivative award (reported as A); reported dollar amount $0.00.
• Vesting (footnotes): RSUs—25% vest June 5, 2027, remainder in 12 equal quarterly installments thereafter (F1). Option award—25% vests April 1, 2027, remainder in 36 equal monthly installments thereafter (F2).
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• No indication this was a sale, purchase, 10b5-1 plan, or tax-withholding event in the provided data.

Context These awards are standard equity compensation intended to align executive incentives with shareholder value; they do not represent an immediate cash investment or sale. The RSUs convert to actual shares upon vesting; the derivative award appears to be an option-like grant that becomes exercisable per the vesting schedule. Such grants are common and should be interpreted as compensation rather than a direct bullish or bearish trading signal.